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Adenosine pretreatment has been shown to be beneficial in several models of 
ischemia-reperfusion. We wished to evaluate whether adenosine pr treatment 
is cardioprotective for prolonged cardiac storage and whether the presence of 
adenosine in the storage media affects the results. Isolated rodent hearts were 
obtained from Sprague-Dawiey rats, mounted on a Langendorff apparatus, 
instrumented with an intraventricular balloon, and ventricularly paced at 300 
beats/min. Four groups of hearts were studied in a 2 × 2 factorial experiment 
(n = 8 to 12 per group). Hearts were subjected to normal perfusion or to 
solution supplemented with adenosine 50 ~mol/L for 10 minutes followed by 
adenosine-free p rfusion for 10 minutes. Hearts then were stored for 8 hours 
at 0 ° C in either University of Wisconsin solution (adenosine 5 mmol/L) or St. 
Thomas' Hospital I I  solution (adenosine free). Adenosine pretreatment in- 
creased tissue levels of adenosine triphosphate before storage (p = 0.04). 
Nonfunction was less common after storage (1/19 versus 6/20 hearts, p < 0.05), 
and diastolic function was better preserved in the adenosine groups in the 
reperfusion phase (p = 0.01). The beneficial effects of adenosine pretreatment 
were independent ofwhich storage solution was used. Developed ressure was 
increased (p < 0.05) and release of creatine kinase and lactate dehydrogenase 
was reduced (p < 0.0001) in hearts treated with University of Wisconsin 
solution compared with those treated with St. Thomas' Hospital solution. 
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These studies suggest that adenosine pretreatment improves recovery after pro- 
longed hypothermic storage and that the presence of adenosine in the preservation 
solution does not alter the results. The experiments provide further evidence that 
extended myocardial protection is better enhanced with University of Wisconsin 
solution than with St. Thomas' Hospital II solution. (J T~ORAC CARDIOVASC SURe 
1995;110:293-301) 
T he cardioprotective properties of adenosine have been well established. 1 With respect o cardiac 
transplantation, adenosine supplementation has 
been shown to be beneficial for extended perfusion, 2 
when added to University of Wisconsin solution 
(UWS) for prolonged hypothermic storage, 3 and in 
the reperfusion phase after prolonged storage with 
St. Thomas' Hospital cardioplegic solution. 4 Ma- 
suda and associates 5 determined that the nucleoside 
transport blocker R75231 did enhance cardiac re- 
covery. Therefore additional studies regarding 
adenosine metabolism and prolonged hypothermic 
storage appeared to be justified. In the following 
series of experiments, we have determined whether 
adenosine pretreatment improves poststorage re- 
sults in hearts protected with either UWS (adeno- 
sine 5 retool/L) or the adenosine-free solution, St. 
Thomas' Hospital II solution (STS). 
Methods 
Hearts were obtained from Sprague-Dawley rats (250 to 
500 gin). All animals received humane care in compliance 
with the "Principles of Laboratory Animal Care" formu- 
lated by the National Society for Medical Research and 
the "Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
Publication No. 86-23, revised 1985). Animals wereanes- 
thetized with an intraperitoneal injection of sodium pen- 
tobarbital. Heparin 200 units was administered intrave- 
nously. A median sternotomy was performed and the 
hearts were rapidly excised and immersed in chilled 
normal saline solution. After excision, hearts were per- 
fused on a Langendorff apparatus with filtered Krebs- 
Henseleit buffer (composition in millimoles per liter: 
NaC1 118, KC1 4.7, KH2PO 4 1.2, CaC12 2.5 MgSO 4 1.2, 
NaHCO 3 25, glucose 11) with a pressure of 100 cm H20. 
The elapsed time from sternotomy tobuffer perfusion was 
approximately 45 seconds. The hearts were ventricularly 
paced at 300 beats/min. The reservoirs and conduits were 
wrapped in a water jacket at 37 ° C. The perfusate was 
gassed with 95% oxygen and 5% carbon dioxide, and the 
pH was adjusted to 7.4. A saline-filled balloon was in- 
serted in the left ventricle via a left atriotomy and fixed to 
the mitral valve ring with a purse-string suture. Th  
balloon volume was varied in 0.02 ml increments from 0 to 
0.4 ml not to exceed an end-diastolic pressure of 30 mm 
Hg. Data were obtained after a 30-minute stabilization 
period before storage and after 45 minutes of reperfusion 
after storage. 
Developed pressure was recorded before and after 
storage with a preischemic balloon volume associated with 
an end-diastolic pressure of 5 mm Hg. Hearts were 
rejected for subsequent s orage if the developed pressure 
was less than 80 mm Hg. Developed pressure after storage 
was not obtained if the end-diastolic pressure xceeded 30 
mm Hg with the 5 mm Hg preischemic balloon volume. 
Compliance curves were assessed by linear regression 
analysis of the end-diastolic pressure-volume data to 
calculate a slope and an X intercept. We 6 have previously 
demonstrated that linear regression provides a r asonable 
model for diastolic function curves. Coronary flow was 
obtained in duplicate by timed collection in the empty 
beating state. 
Cardiac tissue levels of adenine nucleotides, nucleo- 
sides, and degradation products were determined by 
high-performance liquid chromatography as previously 
described.7. 8 Results are expressed as micromoles per 
gram dry weight. 
Creatine kinase release and lactate dehydrogenase re-
lease were assessed uring the 45 minutes of reperfusion 
after the storage int rval. The entire coronary effluent was 
collected. Enzyme release was evaluated with a Hitachi 
Automatic Analyzer 737 (Hitachi Ltd., Tokyo, Japan) and 
an Olympus AU 800 Analyser (Olympus Corp., Lake 
Success, N.Y.), respectively, using spectrophotometry at 
340 nm. The results of these studies are recorded as 
international units per gram dry cardiac weight. 
Study protocol. Adenosine was obtained from Sigma 
Chemical Co. (St. Louis, Mo.). Hearts were divided into 
four groups. A 2 × 2 factorial study design was used to 
evaluate the main effects of adenosine pretreatment ver- 
sus control perfusion and UWS versus STS (n = 8 to 12 
per group). Functional data were obtained after 30 min- 
utes of Langendorff perfusion before ischemia. Hearts 
underwent either an additional 20 minutes of unmodified 
perfusion or adenosine pretreatment (10 minutes of per- 
fusion supplemented with a 50/xmol/L dose of adenosine 
followed by 10 minutes of adenosine-flee perfusion). 
Hearts then underwent aortic root flushing (15 ml/kg) and 
storage (15 to 20 ml) in UWS or STS for 8 hours at 0° C. 
In parallel experiments for the assessment of tissue 
levels of purine metabolites, hearts were mounted on the 
Langendorff apparatus, equilibrated for 30 minutes, and 
subjected to the adenosine pretreatment protocol or 
unmodified perfusion (n = 6 per group). Hearts were then 
immediately immersed in liquid nitrogen for subsequent 
analysis (i.e., prestorage biopsy tissue). 
Statistical analysis. Data analysis was facilitated by 
means of the Statistical Analysis System software (SAS 
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Fig. 1. Developed pressure as a percentage ofprestorage values (mean ± standard eviation, n = 7 to 11 
per group) are presented for each of the four treatment groups. There was no difference between groups 
for adenosine perfusion versus control, but there was better ecovery of poststorage developed pressure in 
the UWS-treated groups. ANOVA, Analysis of variance. 
Institute, Cary, N.C.) and a microcomputer. Categoric vari- 
ables are expressed as n absolute frequency. Continuous 
variables are expressed as a mean _+ standard eviation of 
the original values, as a percentage of control, or as a 
percentage r duction. Data analysis for categoric variables 
was performed by a X 2 test. Data analysis for continuous 
variables was performed with a two-way analysis of variance 
by evaluating the main effects of adenosine pretreatment, 
storage solution, and their interactions. 9 Diastolic function 
was assessed with repeated-measures analysis of variance for 
evaluation of slope and X intercept. 9 Statistical significance 
is assumed for p < 0.05. 
Results 
Adenosine versus control. Before storage, devel- 
oped pressure decreased uring adenosine adminis- 
tration to 87,.8% _+ 6.7% (p < 0.0001) of preadmin- 
istration values and returned to 93.7% _+ 5.2% 
before storage (p < 0.0001). Coronary flow in- 
creased to 115.7% __ 15.4% (p < 0.0001) of pre- 
adenosine wdues during infusion and decreased to 
104.9% _ 5.5% (p < 0.0001) before cardiac storage. 
This corresponds to a delivered adenosine dose of 
12.0 _+ 1.4/~mol per animal. Tissue levels of aden- 
osine triphosphate (ATP) were increased whereas 
levels of adenosine diphosphate and monophos- 
phate were decreased in the adenosine pretreatment 
groups immediately before storage (Table I). 
Altogether' there were seven hearts (1/19 adeno- 
sine pretreatment versus 6/20 buffer perfusion) in 
Table L Prestorage cardiac tissue metabolites 
Control Adenosine 
(n = 6) (n = 6) p Value 
ATP (t~mol/gm) 10.9 -+ 1.4 13.0 _4- 1.5 0.04 
ADP (txmol/gm) 7.2 -+ 1.2 4.9 _+ 1.4 0.02 
AMP 0xmol/gm) 1.6 -+ 0.6 0.6 _+ 0.7 0.04 
TAN 0xmol/gm) 19.7 _+ 1.1 18.5 _+ 1.0 0.10 
Adenosine (p~mol/gm) 0.13 - 0.01 0.09 _+ 0.03 0.04 
Inosine (p~mol/gm) 0.35 -+ 0.02 0.33 _+ 0.03 0.35 
Hypoxanthine 0.039 -- 0.02 0.038 -+ 0.011 0.91 
(~mol/gm) 
Xanthine (pxnol/gm) 0.030 _+ 0.005 0.021 + 0.003 0.008 
The acute effects of adenosine pretreatment onpurine metabolites mea- 
sured 10 minutes after adenosine infusion immediately before storage. 
Values represent mean -+ standard eviation. ATP, Adenosine triphos- 
phate; ADP, adenosine diphosphate; AMP, adenosine monophosphate; 
TAN, total adenine nucleotides; ~, (ATP + ADP + AMP). 
which developed pressure could not be recorded 
after storage (because the poststorage, nd-diastolic 
pressure xceeded the threshold value of 30 mm Hg 
at the preischemic balloon volume associated with 
an end-diastolic pressure of 5 mm Hg). The distri- 
bution of hearts exhibiting nonfunction were one 
heart treated with STS and adenosine versus three 
STS control and three UWS control hearts (p < 
0.05). No other differences with respect to devel- 
oped pressure were measurable between control 
and adenosine-pretreated h arts (Fig. 1). Diastolic 
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Fig. 2. The percent reduction of the X intercept from before to after storage (mean - standard eviation, 
n = 8 to 12 per group) derived from the diastolic function analysis is presented. There was a large reduction 
of the X intercept for all groups (shift to the left), which was limited in the adenosine-treated h arts. There 
was no significant difference between STS and UWS groups. ANOVA, Analysis of variance. 
Table II. Diastolic function 
Slope (mm Hg/ml) X intercept (ml) 
Group N Before storage After storage Before storage After storage 
STS control 10 
STS and adenosine 12 
UWS control 
UWS and adenosine 
p Value (ANOVA) 
p Value (ANOVA) 
p Value (ANOVA) 
p Value (ANOVA) 
87.9 _+ 18.3 175.0 _+ 167.2 0.093 +-- 0.034 -0.041 
+0.052 
96.4 _+ 24.0 133.8 -+ 44.4 0.078 --- 0.037 -0.010 
+0.038 
113.7 -+ 30.9 137.1 + 88.6 0.116 _+ 0.047 0.011 _+ 0.069 
94.0 _+ 18.2 117.8 -+ 14.1 0.090 _+ 0.029 0.020 _+ 0.037 
Storage 0.0067 Storage <0.0001 
Storage * adenosine 0.4145 Storage * adenosine 0.0118 
Storage * solution 0.2035 Storage * solution 0.1384 
Storage * adenosine * solution 0.4060 Storage * adenosine * solution 0.7143 
10 
8 
There was a significant increase in slope and shift to the left of the X intercept after storage. The reduction of X intercept was decreased in the 
adenosine-treated hearts (storage * adenosine effect). The ast risks refer to the interaction term. 
function results for slope and X intercept are pre- 
sented in Table II. Overall, a large increase in slope 
and a decrease in X intercept were observed from 
prestorage to poststorage values. The increase in 
slope was not influenced by the presence of adeno- 
sine, although the reduction in X intercept was 
limited in the adenosine-treated hearts (p = 0.0118). 
The poststorage X intercept, expressed as a percent 
reduction of prestorage values, is presented in Fig. 
2. No differences in coronary flow were noted 
among any of the groups, with values ranging from 
60.3% _+ 14.9% to 64.6% _+ 10.2%. No differences 
in creatine kinase (Fig. 3) or lactate dehydrogenase 
release (Fig. 4) were noted between the control and 
adenosine-treated hearts. 
STS versus UWS. The return of developed pres- 
sure was greater after storage in the UWS versus the 
STS groups (Fig. 1). No significant differences in the 
poststorage diastolic function were observed, al- 
though the decrease in X intercept tended to be less 
for both UWS groups (p = 0.1384). The decreases in
creatine kinase release (Fig. 3) and lactate dehydro- 
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Fig. 3. Results for creatine ldnase release during the 45-minute reperfusion phase are presented. The 
values for the UWS groups were significantly lower than those for the STS hearts. There was no significant 
difference between control and adenosine pretreatment. ANOVA, Analysis of variance. 
0 CONTROL 
STS 
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Fig. 4. The results for lactate dehydrogenase (mean -+ standard eviation, n = 8 to 12 per group) are 
presenred. There was a significant reduction in the UWS-treated hearts compared with STS groups. There 
was no reduction oted for adenosine pretreatment. ANOVA, Analysis of variance. 
genase release (Fig. 4) were highly significant (p <
0.0001) in the UWS groups compared with the STS 
groups. 
Discussion 
Our study was designed to assess the potential 
benefit of adenosine pretreatment before prolonged 
hypothermic storage, similar to the documented 
improvement noted with models of normothermic 
global ischemia) °-la Important differences were 
identified with adenosine pretreatment with respect 
to prestorage adenine nucleotides, diastolic dysfunc- 
tion, and, as a result of excessive end-diastolic 
pressures, measurable systolic function. These 
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changes in left ventricular diastolic parameters with 
adenosine would be extremely helpful after cardiac 
transplantation (especially in recipients with preex- 
isting pulmonary hypertension) with an allograft 
right ventricle unaccustomed to the increased after- 
load. The changes noted in our experiments oc- 
curred irrespective of which storage solution was 
used for the studies. 
The cardioprotective role of adenosine has been 
evaluated in many ischemia-reperfusion models in- 
cluding global ischemia, 1°q2 regional ischemia, 13' 14 
cardioplegia,15, 16and ventricular assistJ 7 Murray 
and colleagues is initially described ischemic precon- 
ditioning whereby brief episodes of coronary isch- 
emia protect against subsequent prolonged coronary 
occlusions. The mechanisms responsible for isch- 
emic preconditioning are uncertain, although re- 
ports by Liu, 19 Thornton, 2° and their colleagues 
have provided evidence to implicate adenosine A1- 
selective receptor activation as an important event 
(caused by interstitial adenosine accumulation). 
Adenosine or Al-selective agonists mimic the pro- 
tection by ischemic preconditioning, whereas A2- 
selective agonists are ineffective and the temporal 
pattern is consistent with preconditioning. Adeno- 
sine receptor antagonists block the cardioprotection 
provided by ischemic preconditioning. Although the 
data supporting adenosine are persuasive, the ulti- 
mate effector is incompletely understood. 
Adenosine supplementation f extended cardiac 
allograft preservation helped maintain left ventric- 
ular blood flow. 2 Adenosine was included in the 
UWS formulation because ATP synthesis was facil- 
itated during hypothermic kidney perfusion. 21 More 
recent studies by Lasley and Mentzer 3directly eval- 
uated the contribution of adenosine to UWS for 
cardiac preservation. Interstitial adenosine concen- 
trations were 20 to 40 times greater according to 
microdialysis and improvement in functional recov- 
ery. Other authors have examined the role of either 
a nucleoside transport blocker 5or acadesine 22and 
documented improvement after hypothermic stor- 
age. It appears that maneuvers to enhance ndoge- 
nous adenosine or provision of exogenous adeno- 
sine exert positive effects for extended cardiac 
allograft preservation, similar to those achieved in 
other ischemia-reperfusion models. 
We previously conducted experiments evaluating 
the addition of a nucleoside transport blocker 23 to 
UWS and determined that additional manipulations 
of adenosine metabolism further enhance cardiac 
recovery. We were therefore stimulated to explore 
whether adenosine pretreatment would be effective. 
Because we were uncertain whether the adenosine 
content of UWS would obscure any putative aden- 
osine pretreatment contribution, a factorial study 
design was used in which both pretreatment and 
study solution were analyzed simultaneously. Ac- 
cordingly, differences resulting from the effects of 
adenosine administration versus storage conditions 
have been separately reported. The adenosine pro- 
tocol used in these studies was selected after pilot 
experiments (n = 2 per group) evaluating adenosine 
concentrations of 25 to 100/xmol/L with and without 
an adenosine-free interval after the adenosine infu- 
sion. 
It cannot be ascertained whether the improve- 
ment noted in the current experiments was 
mediated by Al-receptor or A2-receptor activation 
(or both) or was not receptor mediated. During the 
adenosine infusion, developed pressure was re- 
duced, which suggests At-receptor activation, 
whereas coronary flow increased, which is indica- 
tive of A2-receptor activation. Bradycardia occurred 
during the adenosine infusion in our pilot studies, 
likely related to Al-receptor activation (which was 
prevented uring our reported experiments by pac- 
ing all hearts). For the preconditioning effect, the 
evidence from the literature is most supportive of 
Al-receptor involvement. Additional investigations 
involving selective Al-receptor or Az-receptor ago- 
nists would help determine which receptor is pri- 
marily affected. Furthermore, we recognize that the 
buffer-perfused, Langendorff apparatus has signifi- 
cant limitations and that experiments involving 
blood perfusion would be helpful. 
Our biopsy results differentiated between control 
perfusion and adenosine pretreatment with respect 
to adenine nucleotides and nucleosides. Our proto- 
col indicates an important non-receptor-mediated 
contribution of adenosine. This contribution may 
simulate the clinical situation, in which hearts from 
organ donors may be ischemically damaged before 
harvest. It is conceivable that adenosine may facili- 
tate de novo adenine nucleotide synthesis in such 
circumstances. Cardiac biopsies were performed 10 
minutes after adenosine infusion, at which time 
adenosine and xanthine levels were reduced, 
whereas inosine and hypoxanthine were similar in 
the adenosine pretreated and the control hearts. It is 
probable that biopsy tissue obtained uring adeno- 
sine infusion would have demonstrated increased 
nucleosides and degradation products. 
Ischemic ontracture has been proposed as one of 
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the key limitations for extended cardiac storage 24 
and may explain the differential temporal protection 
for abdominal versus cardiac allografts provided by 
UWS. The increase in diastolic pressure was tightly 
correlated with the decrease in tissue content of 
ATP in rabbit studies reported by Stringham and 
associates. 24 The beneficial response that we de- 
tected for diastolic parameters with adenosine pre- 
treatment may relate to the greater ATP content 
before storage. Other studies uggest that adenosine 
pretreatment slows the decline of ATP and limits 
intracellular calcium accumulationy both of 
which would favorably affect contracture develop- 
ment. 
One of the potential benefits of adenosine is 
vascular dilatation. Dilatation is pertinent because 
cardioplegic solutions 26 and UWS 27' 28 appear to 
impair coronary endothelium-dependent relaxation, 
which may be mediated in part by oxygen-derived 
free radical injury. 29 Conflicting evidence has been 
reported concerning the role of adenosine in limit- 
ing microcirculatory d sfunction, 3°'31 which may be 
due to model differences. Galiflanes and Hearse 4
have reported that adenosine administered during 
reperfusion hastened early recovery of contractile 
function and coronary flow of transplanted hearts. 
In any case, global coronary flow was reduced 
equally after storage in each of the four groups in 
our experiments, and no apparent improvement 
with adenosine pretreatment was detected. 
A valid concern regarding the results of these 
experiments i  the applicability of adenosine infu- 
sion into clinical practice. Inotrope-dependent do-
nors may be intolerant of large-dose adenosine 
infusion caused by hypotension. Adenosine admin- 
istration could require cardiopulmonary support or 
could be performed uring ex vivo perfusion imme- 
diately after cardiac excision. Alternatively, Al-re- 
ceptor agonists rather than adenosine may be better 
tolerated in such circumstances. 
The second principal result of these experiments 
is that UWS is preferred instead of STS for ex- 
tended myocardial preservation. With notable ex- 
ceptions, 27'32 experimental bypothermic ardiac 
storage with UWS is better than storage with other 
storage media. 3'33-4o The present s udy is consistent 
with the overall recommendation from the aggre- 
gated investigations that UWS is preferred for al- 
lograft protection. The clinical trial data obtained 
with conventional organ ischemic times, that is, less 
than 4 hours, have been favorable 41-43 but cannot be 
considered conclusive. 
The mechanism(s) responsible for the reported 
benefit of UWS with respect o cardiac storage is 
uncertain. The composition of UWS is unique, and 
several "UWS-like" formulations have been used 
experimentally. Ko and associates 44 have performed 
the most critical attempt to date to determine the 
importance of the different components of UWS 
using a servo-volume pump to evaluate left ventric- 
ular end-systolic and end-diastolic pressure-volume 
relationships. In their studies, an intracellular con- 
centration of potassium, hydroxyethyl starch, and to 
a lesser degree lactobionate were considered to be 
essential factors. Adenosine, itself an important 
component, was included in all of the UWS prepa- 
rations used in their studies. 3 Other investigations 
have suggested that further modification to the 
UWS formulation can provide additional benefits 
for cardiac allograft recovery. 6' 23, 45 Whether these 
findings can be translated into improvements in
meaningful c inical end points is arguable. However, 
benefits would probably be observed after procure- 
ment of organs from high-risk donors 46 by virtue of 
prolonged anticipated organ ischemic time, exces- 
sive inotropic use, small size, or advanced age. 
We express our appreciation to Mara Svikis for assis- 
tance in the preparation of the manuscript. We also 
acknowledge the Multiple Organ Retrieval and Exchange 
Program, Dupont Canada Ltd., for donation f the Uni- 
versity of Wisconsin solution used in these studi s. 
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